NASDAQ:CLDX Celldex Therapeutics Q1 2025 Earnings Results & Report $28.83 +0.30 (+1.05%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$28.81 -0.02 (-0.07%) As of 11/13/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Celldex Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.81 versus the -$0.75 consensus estimate, while revenue of $695 thousand fell short of the $1.08 million estimate by $384 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call12:00 AM ET Celldex Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.75Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCelldex Therapeutics Revenue ResultsActual Revenue$695 thousandExpected Revenue$1.08 millionBeat/MissMissed by -$384.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Celldex Therapeutics Q1 2025 Earnings FAQ Did Celldex Therapeutics beat earnings estimates for Q1 2025? Celldex Therapeutics (NASDAQ:CLDX) reported earnings of -$0.81 per share for Q1 2025, missing the consensus estimate of -$0.75. The report was announced on Thursday, May 8, 2025. What was Celldex Therapeutics' revenue for Q1 2025? Celldex Therapeutics reported revenue of $695 thousand for Q1 2025, against a consensus estimate of $1.08 million. Celldex Therapeutics Earnings HeadlinesHC Wainwright Has Strong Estimate for CLDX FY2026 EarningsNovember 12 at 1:43 AM | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Expected to Rise, Morgan Stanley Analyst SaysNovember 11 at 2:51 AM | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 14 at 1:00 AM | Behind the Markets (Ad)Celldex Therapeutics (NASDAQ:CLDX) Stock Gets Price Target Bump from Canaccord Genuity GroupNovember 11 at 2:06 AM | americanbankingnews.comHead to Head Survey: Oncobiologics (NASDAQ:OTLK) and Celldex Therapeutics (NASDAQ:CLDX)November 9, 2026 | americanbankingnews.comCelldex Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 6, 2026 | markets.businessinsider.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways. The company is headquartered in Hampton, New Jersey, and is led by co-founder Anthony Marucci, its president and chief executive officer.View Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
